Clascoterone is under clinical development by Cosmo Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Clascoterone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Clascoterone in Pancreatic Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Clascoterone overview

Clascoterone (Winlevi) is a cortexolone 17alpha-propionate derivative acts as anti-acne agent. It is formulated as cream for topical application. Winlevi is indicated for treatment of acne vulgaris in patients with 12 years of age and older.
Clascoterone (CB-0301, Winlevi) is under development for the treatment of acne vulgaris, solid tumors including androgen-independent prostate adenocarcinoma, relapsed/refractory pancreatic adenocarcinoma, androgenetic alopecia, pilonidal sinus disease and relapsed/refractory triple negative breast cancer (TNBC). The drug candidate is a new chemical entity. It is administered through cutaneous (topical) route. The drug candidate is derived from 11-deoxycortisone that acts by targeting androgen receptor. It is developed based on Matrix MMX technology. It was also under development for the treatment of hirsutism.

Cosmo Pharmaceuticals overview

Cosmo Pharmaceuticals (Cosmo) develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company’s pipeline products include breezula for androgenetic alopecia; CB-01-35 targets ulcerative colitis and proctitis; CB-01-33 treats bile acid diarrhea; and CB-03-10 targets pancreatic and colon cancers. It also offers eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. The company’s manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland

For a complete picture of Clascoterone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.